6 min read
TL;DR: Will ketamine FDA approval for depression become a reality? This article explores why IV ketamine for depression is one of the strongest drug repurposing candidates under consideration by the FDA and examines the growing scientific evidence supporting its use for treatment-resistant depression.
- IV ketamine for depression has decades of clinical use and a well-established safety profile
- Research continues to demonstrate the effectiveness of ketamine for treatment resistant depression TRD
- FDA approval of Spravato supports the scientific rationale behind ketamine-based depression treatments
- Ketamine can provide rapid symptom relief compared to traditional antidepressants
- Expanded ketamine FDA approval could improve access to affordable, evidence-based mental health treatment
The FDA Is Asking an Important Question
In 2026, the U.S. Food and Drug Administration (FDA) opened a public docket seeking input on an important issue: which existing FDA-approved medications should be considered for new uses to address major unmet medical needs?
The initiative focuses on drug repurposing, a process that identifies new therapeutic applications for medications with established safety profiles and extensive clinical experience.
As the Co-Founder and CEO of Ketamine Clinics Los Angeles, I believe IV ketamine for depression is one of the strongest candidates under consideration.
Few medications more closely match the FDA's stated criteria, and few have the potential to impact as many lives.
What Is Drug Repurposing?
Drug repurposing allows regulators and researchers to build upon decades of existing knowledge about a medication rather than starting from scratch.
According to the FDA, ideal candidates are drugs that:
- Have compelling evidence supporting a new use
- Use the same route of administration and dosage form already approved
- Have a comparable safety profile for the new indication
- Lack sufficient commercial incentive for a manufacturer to pursue formal approval
IV ketamine checks every box.
The growing discussion around ketamine FDA approval highlights the benefits of repurposing a medication that has already demonstrated decades of clinical safety and effectiveness.
The Mental Health Crisis Demands Better Solutions
Depression remains one of the leading causes of disability worldwide. The World Health Organization estimates that hundreds of millions of people are affected by depression, making it one of the world's most significant public health challenges.
According to the Centers for Disease Control and Prevention, nearly 49,000 Americans died by suicide in 2024. Millions struggle with severe depression, treatment-resistant depression (TRD), PTSD, anxiety disorders, and suicidal thoughts every year.
Young people have been particularly affected. CDC data show that the percentage of U.S. high school students reporting persistent feelings of sadness or hopelessness increased from 26% in 2009 to 42% in 2021.
While traditional antidepressants help many patients, they often require weeks or months before meaningful improvement occurs. Unfortunately, many patients do not respond adequately despite trying multiple medications.
This is where ketamine is especially important.
The Evidence for IV Ketamine Continues to Grow
Ketamine is not a new medication.
The FDA first approved ketamine in 1970, and it has been used safely for more than five decades in anesthesia, emergency medicine, pain management, and critical care.
Over the past two decades, researchers have generated a substantial body of evidence demonstrating ketamine's antidepressant effects. Today, hundreds of published studies, randomized controlled trials, systematic reviews, and meta-analyses support the use of ketamine treatment resistant depression protocols and IV ketamine for depression.
One of ketamine's most remarkable characteristics is speed.
Unlike conventional antidepressants, which often require weeks to achieve meaningful improvement, ketamine frequently produces significant symptom reduction within hours or days.
For individuals experiencing severe depression or suicidal thoughts, that difference can be life changing.
The effectiveness of ketamine has become one of the most studied topics in modern psychiatric medicine, particularly for patients who have exhausted conventional treatment options.
FDA Recognition Already Exists Through Spravato
Importantly, the FDA has already recognized the therapeutic significance of ketamine's mechanism of action.
In 2019, the agency approved Spravato (esketamine) for treatment-resistant depression.
Later, the FDA expanded approval to include depressive symptoms associated with acute suicidal ideation or behavior.
Esketamine is derived from ketamine and acts through a similar biological pathway.
The existence of an FDA approved ketamine derived psychiatric treatment further reinforces the scientific rationale supporting ketamine's role in depression treatment.
The discussion of ketamine vs Spravato often centers on delivery method, formulation, and clinical outcomes, but both therapies demonstrate the growing acceptance of ketamine-based approaches for depression.
What About Safety?
One of the strongest arguments for IV ketamine is its extensive safety history.
Ketamine has been used in medicine for more than 50 years and has been administered to millions of patients worldwide.
At Ketamine Clinics Los Angeles, we have provided more than 35,000 IV ketamine infusions to over 6,000 patients since 2014.
During that time, we have observed a strong safety profile when treatment is administered in an appropriate medical setting by trained professionals. We have not experienced any treatment-related deaths or persistent, serious treatment-related complications.
Our clinical outcomes have also been encouraging, with response rates exceeding 70% on the Montgomery Åsberg Depression Rating Scale (MADRS) and exceeding 80% on certain other outcome measures.
These results further support the effectiveness of ketamine when administered as part of a comprehensive ketamine therapy program.
Ketamine Versus Other Treatment Options
The evidence supporting ketamine continues to become more compelling.
In the landmark ELEKT D trial published in The New England Journal of Medicine, intravenous ketamine was found to be noninferior to electroconvulsive therapy (ECT) for nonpsychotic treatment-resistant depression. Researchers observed higher response rates in the ketamine group while avoiding many of the cognitive side effects commonly associated with ECT.
These findings suggest that ketamine deserves serious consideration among the most effective treatments currently available for treatment-resistant depression.
A Public Health Opportunity
One of the most important aspects of this discussion has nothing to do with science.
It has to do with economics.
Because ketamine is a generic medication, there is little financial incentive for a manufacturer to spend the substantial resources required to pursue a new FDA indication.
As a result, a treatment supported by extensive evidence and real-world clinical experience remains caught in a regulatory gap.
This is precisely the type of problem the FDA's drug repurposing initiative was designed to solve.
Unlike many emerging therapies, ketamine is already widely available, inexpensive, familiar to physicians, and recognized by the World Health Organization as an Essential Medicine.
Expanding recognition of its role in depression treatment could improve access, reduce healthcare costs, and potentially save lives.
Why This Matters Now
The United States is facing a growing mental health crisis.
Patients need more effective treatment options.
Clinicians need tools that work rapidly for severe depression and suicidality.
Healthcare systems need solutions that are evidence-based, scalable, and affordable.
Among all potential drug repurposing candidates, intravenous racemic ketamine stands out because it combines:
- Strong scientific evidence
- Extensive real-world clinical experience
- A well-established safety profile
- Significant unmet medical need
- Low cost and broad availability
- Limited commercial sponsorship
Few candidates more closely match the FDA's stated goals.
As the FDA evaluates opportunities for drug repurposing, intravenous ketamine deserves serious consideration as one of the most compelling candidates available today.
Greater progress toward ketamine FDA approval could expand access to life-changing ketamine therapy for patients living with treatment resistant depression TRD and other serious mental health conditions.
Frequently Asked Questions About IV Ketamine for Depression
Is IV ketamine FDA approved for depression?
No. Intravenous racemic ketamine is FDA-approved as an anesthetic but does not currently have a specific FDA indication for depression. Physicians may legally prescribe approved medications for off label uses when supported by scientific evidence and clinical judgment.
What is the difference between ketamine and Spravato?
Spravato contains esketamine, a metabolite of ketamine, and is administered as a nasal spray. Intravenous ketamine uses racemic ketamine, which contains both the R and S forms of the molecule.
Is ketamine effective for treatment-resistant depression?
Hundreds of randomized controlled trials, systematic reviews, and meta-analyses have found that ketamine can produce rapid antidepressant effects in most patients with treatment-resistant depression.
How quickly does ketamine work?
Traditional antidepressants often require several weeks before meaningful improvement occurs. Ketamine can produce noticeable symptom relief within hours or days for some individuals.
Can ketamine help with suicidal thoughts?
Yes, ketamine may rapidly reduce suicidal ideation in the majority of patients experiencing severe depression.
Is IV ketamine safe?
Yes. Ketamine has been used in medicine since 1970 and has been administered to tens of millions of patients worldwide. When administered by trained healthcare professionals in an appropriate medical setting, ketamine has a well-characterized safety profile.
Why hasn't ketamine been FDA approved for depression?
Because ketamine is a generic medication, there is limited financial incentive for manufacturers to invest in obtaining a new FDA indication despite substantial scientific evidence supporting its use.
Is ketamine more effective than ECT?
The ELEKT D trial found intravenous ketamine to be more effective aka "noninferior" to ECT for nonpsychotic treatment-resistant depression, with higher observed response rates in the ketamine group.
References
Anand A, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine. 2023.
Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta Analysis. American Journal of Psychiatry. 2018.
Bahji A, Vazquez GH, Zarate CA Jr. Comparative Efficacy of Racemic Ketamine and Esketamine for Depression: A Systematic Review and Meta-Analysis. Journal of Affective Disorders. 2021.
Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019.
Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017.
World Health Organization. Depression Fact Sheet.
World Health Organization. WHO Model List of Essential Medicines.
Centers for Disease Control and Prevention. Suicide Data and Statistics.
Centers for Disease Control and Prevention. Youth Risk Behavior Survey Data Summary and Trends Report.
